Liom achieves Breakthrough in Miniaturization of its Non-invasive Biomarker Monitoring Tech Platform and extends Series A Funding to CHF 38 MillionPfäffikon, Switzerland, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Liom, a pioneer in non-invasive biomarker monitoring and the developer of the world’s first non-invasive glucose-monitoring wearable, today announced a CHF 13 million extension of its Series A financing round. This brings its total Series A to CHF 38 million and its total funding to date to CHF 63 million. The round was led by previous lead investors, with new participation from Red Bull Ventures, Marc Maurer (former co-CEO of On Running), Melih Odemis (former co-founder and CTO of Yemeksepeti), Alejo Costa Ribalta, partner of venture capital firm CRB Health Tech and former senior executive of Philips and GE Healthcare, and others.
